Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

NCT04061200 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes With Renal Manifestations

Interventions

DRUG: Semaglutide, 1.34 mg/mL
OTHER: Placebo, 1,34 mg/mL
DRUG: Empagliflozin 25 MG

Sponsor

Steno Diabetes Center Copenhagen

Collaborators

[object Object]